Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226081524> ?p ?o ?g. }
- W4226081524 endingPage "1759720X2210902" @default.
- W4226081524 startingPage "1759720X2210902" @default.
- W4226081524 abstract "The aim of this study was to assess the cause-specific mortality rate related to COVID-19 (CMR) in patients with rheumatic and musculoskeletal diseases (RMDs) and COVID-19 and to analyze the role of the different RMDs in their mortality risk.An observational longitudinal study was conducted during the first pandemic wave in our center. Patients with the diagnosis of RMDs and COVID-19 were included. Main outcome is the death related to COVID-19. Independent variable - type of RMDs: autoimmune rheumatic diseases (ARD), such as chronic inflammatory arthritis (CIA) and connective tissue diseases (CTD) and non-autoimmune Rheumatic Diseases (non-ARD). Survival techniques were used to estimate the CMR per 1000 patients-month with a 95% confidence interval (CI), and Cox multivariate regression analysis was run to examine the effect of ARD compared to non-ARD on mortality risk adjusted by confounders. Results were expressed by Hazard Ratio (HR) and CI.Overall, 405 patients were included (642.5 patients-month). During the study period, 44 (10.86%) deaths were recorded. CMR was 68.48 (50.96-92.01). After adjusting for confounders, HR of mortality in ARD compared to non-ARD did not achieve statistical significance [HR: 1.15 (0.64-2.07)], neither CTD versus CIA nor CTD versus non-ARD. Age and certain comorbidities which are being diagnosed in March compared to April or May [HR: 2.43 (1.1-5.55)] increased the mortality risk. Glucocorticoids and disease-modifying antirheumatic drugs (DMARDs) dropped from the final model.In patients with RMDs and COVID-19, CMR was 6.8% patients-month. This study shows that mortality risk is higher in males, older patients, and similar between CTD, CIA, and non-ARD. COVID-19 management improved after the first month of pandemic.Mortality related to the outbreak of COVID-19 in patients with rheumatic and musculoskeletal diseasesWhy was this study done? - To report the COVID-19-specific mortality rate in patients with a variety of RMDs during the first pandemic peak in a tertiary hospital in Madrid and to analyze the role of specific types of ARD and other possible factors in the risk of death related to COVID-19. What did the researchers do? - We performed a retrospective observational study during the first wave of the COVID-19 pandemic in Madrid, Spain. What did the researchers find? - In this study, neither the different diagnoses of RMDs, including CIA, CTD, or non-ARD disease or its treatment were not implicated as a potential risk of death related to COVID-19- In consonance with other studies, RMDs patients and COVID-19, older age, male sex, and certain comorbidities implied more mortality risk- Our data reflect COVID-19 severity in a particular context, time, and population. In times of the absence of COVID-19 vaccine, healthcare, social, and political measures taken to contain the coronavirus outbreak have worked properly. What do the findings mean? - The presence of comorbidities in RMDs patients represents a greater risk than the different types of RMDs themselves, in the development of COVID-19 fatal outcome. It is important to integrate the control of comorbidities in the daily management." @default.
- W4226081524 created "2022-05-05" @default.
- W4226081524 creator A5013969287 @default.
- W4226081524 creator A5018239952 @default.
- W4226081524 creator A5023890220 @default.
- W4226081524 creator A5025761116 @default.
- W4226081524 creator A5041835945 @default.
- W4226081524 creator A5052259540 @default.
- W4226081524 creator A5064534346 @default.
- W4226081524 creator A5065547202 @default.
- W4226081524 creator A5077234403 @default.
- W4226081524 creator A5083628642 @default.
- W4226081524 creator A5085479328 @default.
- W4226081524 date "2022-01-01" @default.
- W4226081524 modified "2023-10-14" @default.
- W4226081524 title "Mortality related to COVID-19 in patients with rheumatic and musculoskeletal diseases, first wave of the outbreak: a single-center study" @default.
- W4226081524 cites W2599076725 @default.
- W4226081524 cites W2799398492 @default.
- W4226081524 cites W3001118548 @default.
- W4226081524 cites W3001465255 @default.
- W4226081524 cites W3002108456 @default.
- W4226081524 cites W3006355661 @default.
- W4226081524 cites W3006485704 @default.
- W4226081524 cites W3008028633 @default.
- W4226081524 cites W3008090866 @default.
- W4226081524 cites W3009885589 @default.
- W4226081524 cites W3013967887 @default.
- W4226081524 cites W3014972620 @default.
- W4226081524 cites W3015782440 @default.
- W4226081524 cites W3015826289 @default.
- W4226081524 cites W3016350662 @default.
- W4226081524 cites W3016535995 @default.
- W4226081524 cites W3018029174 @default.
- W4226081524 cites W3018811022 @default.
- W4226081524 cites W3020646040 @default.
- W4226081524 cites W3024016727 @default.
- W4226081524 cites W3024177957 @default.
- W4226081524 cites W3024193040 @default.
- W4226081524 cites W3025283885 @default.
- W4226081524 cites W3028583791 @default.
- W4226081524 cites W3030308448 @default.
- W4226081524 cites W3033739008 @default.
- W4226081524 cites W3034857588 @default.
- W4226081524 cites W3038582169 @default.
- W4226081524 cites W3045623013 @default.
- W4226081524 cites W3046768463 @default.
- W4226081524 cites W3047144258 @default.
- W4226081524 cites W3047658716 @default.
- W4226081524 cites W3048371719 @default.
- W4226081524 cites W3048431881 @default.
- W4226081524 cites W3081452237 @default.
- W4226081524 cites W3092151577 @default.
- W4226081524 cites W3106918066 @default.
- W4226081524 cites W3111555681 @default.
- W4226081524 cites W3120992736 @default.
- W4226081524 cites W3122628681 @default.
- W4226081524 cites W3123185440 @default.
- W4226081524 cites W3124810175 @default.
- W4226081524 cites W3125617276 @default.
- W4226081524 cites W3130465197 @default.
- W4226081524 cites W3134802489 @default.
- W4226081524 cites W3134935611 @default.
- W4226081524 cites W3145331821 @default.
- W4226081524 cites W3165656738 @default.
- W4226081524 cites W3166132123 @default.
- W4226081524 cites W3188183974 @default.
- W4226081524 cites W3196332529 @default.
- W4226081524 cites W3200299601 @default.
- W4226081524 cites W3214322228 @default.
- W4226081524 cites W4210642183 @default.
- W4226081524 cites W4248429808 @default.
- W4226081524 doi "https://doi.org/10.1177/1759720x221090296" @default.
- W4226081524 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35510167" @default.
- W4226081524 hasPublicationYear "2022" @default.
- W4226081524 type Work @default.
- W4226081524 citedByCount "3" @default.
- W4226081524 countsByYear W42260815242023 @default.
- W4226081524 crossrefType "journal-article" @default.
- W4226081524 hasAuthorship W4226081524A5013969287 @default.
- W4226081524 hasAuthorship W4226081524A5018239952 @default.
- W4226081524 hasAuthorship W4226081524A5023890220 @default.
- W4226081524 hasAuthorship W4226081524A5025761116 @default.
- W4226081524 hasAuthorship W4226081524A5041835945 @default.
- W4226081524 hasAuthorship W4226081524A5052259540 @default.
- W4226081524 hasAuthorship W4226081524A5064534346 @default.
- W4226081524 hasAuthorship W4226081524A5065547202 @default.
- W4226081524 hasAuthorship W4226081524A5077234403 @default.
- W4226081524 hasAuthorship W4226081524A5083628642 @default.
- W4226081524 hasAuthorship W4226081524A5085479328 @default.
- W4226081524 hasBestOaLocation W42260815241 @default.
- W4226081524 hasConcept C126322002 @default.
- W4226081524 hasConcept C198451711 @default.
- W4226081524 hasConcept C207103383 @default.
- W4226081524 hasConcept C23131810 @default.
- W4226081524 hasConcept C2780073493 @default.
- W4226081524 hasConcept C44249647 @default.
- W4226081524 hasConcept C50382708 @default.
- W4226081524 hasConcept C71924100 @default.